Jessica Jou

Dr. Jessica Jou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JJJessica Jou
Jessica Jou
KHKevin J. Harrington
Kevin J. Harrington
MZMai-Britt Zocca
Mai-Britt Zocca
EEEva Ehrnrooth
Eva Ehrnrooth
ECEzra E.W. Cohen
Ezra E.W. Cohen
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we briefly outline the principles underlying cancer vaccine therapy with a focus on novel vaccine platforms and antigens, underscoring the renewed optimism. Numerous strategies have been investigated to overcome immunosuppressive mechanisms of the tumor microenvironment (TME) and counteract tumor escape, including improving antigen selection, refining delivery platforms, and use of combination therapies. Several new cancer vaccine platforms and antigen targets are under development. In an effort to amplify tumor-specific T-cell responses, a heterologous prime-boost antigen delivery strategy is increasingly used for virus-based vaccines. Viruses have also been engineered to express targeted antigens and immunomodulatory molecules simultaneously, to favorably modify the TME. Nanoparticle systems have shown promise as delivery vectors for cancer vaccines in preclinical research. T-win is another platform targeting both tumor cells and the TME, using peptide-based vaccines that engage and activate T cells to target immunoregulatory molecules expressed on immunosuppressive and malignant cells. With the availability of next-generation sequencing, algorithms for neoantigen selection are emerging, and several bioinformatic platforms are available to select therapeutically relevant neoantigen targets for developing personalized therapies. However, more research is needed before the use of neoepitope prediction and personalized immunotherapy becomes commonplace. Taken together, the field of therapeutic cancer vaccines is fast evolving, with the promise of potential synergy with existing immunotherapies for long-term cancer treatment.

22 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JZJade Zhou
Jade Zhou
JJJessica Jou
Jessica Jou
ECEzra Cohen
Ezra Cohen
The rising incidence of oropharyngeal squamous cell cancers (OPSCC) in the United States is largely attributed to HPV. Prophylactic HPV vaccines have demonstrated effectiveness against oral infection of HPV 16 and HPV 18. We review the global epidemiology and biology of HPV-related cancers as well as the development of HPV vaccines and their use worldwide. We also review the various strategies and challenges in development of therapeutic HPV vaccines.

1 March 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
JJJessica Jou
Jessica Jou
ECElizabeth Coulter
Elizabeth Coulter
TRTraci Roberts
Traci Roberts
PBPratibha Binder
Pratibha Binder
CSCheryl Saenz
Cheryl Saenz
RERamez N. Eskander
Ramez N. Eskander

1 August 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
JJJessica Jou
Jessica Jou
ABAllison Brodsky
Allison Brodsky
LCLindsey Charo
Lindsey Charo
PBPratibha Binder
Pratibha Binder
CSCheryl Saenz
Cheryl Saenz
SPSteve Plaxe
Steve Plaxe

1 April 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
JJJessica Jou
Jessica Jou
ZZZoe Zimmer
Zoe Zimmer
LCLindsey Charo
Lindsey Charo
CYChristopher Yau
Christopher Yau
CSCheryl Saenz
Cheryl Saenz
PBPratibha Binder
Pratibha Binder

24 August 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JJJessica Jou
Jessica Jou
SKShumei Kato
Shumei Kato
HMHirotaka Miyashita
Hirotaka Miyashita
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
Our objective was to characterize cancer-immunity marker expression in gynecologic cancers and compare immune landscapes between gynecologic tumor subtypes and with nongynecologic solid tumors. RNA expression levels of 51 cancer-immunity markers were analyzed in patients with gynecologic cancers versus nongynecologic cancers, and normalized to a reference population of 735 control cancers, ranked from 0 to 100, and categorized as low (0–24), moderate (25–74), or high (75–100) percentile rank. Of the 72 patients studied, 43 (60%) had ovarian, 24 (33%) uterine, and 5 (7%) cervical cancer. No two immune profiles were identical according to expression rank (0–100) or rank level (low, moderate, or high). Patients with cervical cancer had significantly higher expression level ranks of immune activating, proinflammatory, tumor-infiltrating lymphocyte markers, and checkpoints than patients with uterine or ovarian cancer (P < 0.001 for all comparisons). However, there were no significant differences in immune marker expression between uterine and ovarian cancers. Tumors with PD-L1 tumor proportional score (TPS) ≥1% versus 0% had significantly higher expression levels of proinflammatory markers (58 vs. 49%, P = 0.0004). Compared to patients with nongynecologic cancers, more patients with gynecologic cancers express high levels of IDO-1 (44 vs. 13%, P < 0.001), LAG3 (35 vs. 21%, P = 0.008), and IL10 (31 vs. 15%, P = 0.002.) Patients with gynecologic cancers have complex and heterogeneous immune landscapes that are distinct from patient to patient and from other solid tumors. High levels of IDO1 and LAG3 suggest that clinical trials with IDO1 inhibitors or LAG3 inhibitors, respectively, may be warranted in gynecologic cancers.